NYSE:MED Medifast (MED) Stock Price, News & Analysis $18.39 -0.30 (-1.61%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Medifast Stock (NYSE:MED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medifast alerts:Sign Up Key Stats Today's Range$17.89▼$18.7550-Day Range$17.31▼$19.9852-Week Range$17.07▼$76.42Volume162,505 shsAverage Volume392,483 shsMarket Capitalization$201.13 millionP/E Ratio6.86Dividend YieldN/APrice Target$17.50Consensus RatingSell Company OverviewMedifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Medifast Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks33rd Percentile Overall ScoreMED MarketRank™: Medifast scored higher than 33% of companies evaluated by MarketBeat, and ranked 119th out of 143 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingMedifast has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMedifast has received no research coverage in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth-16.07% Earnings GrowthEarnings for Medifast are expected to decrease by -16.07% in the coming year, from $1.12 to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 6.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 6.86, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 21.90.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.68% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Medifast has recently decreased by 3.80%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Medifast is 246.27%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on EPS estimates, Medifast will have a dividend payout ratio of 702.13% in the coming year. This indicates that Medifast may not be able to sustain their current dividend.Read more about Medifast's dividend. Sustainability and ESG2.0 / 5Environmental Score-4.00 Percentage of Shares Shorted16.68% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Medifast has recently decreased by 3.80%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Medifast this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Medifast to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesWashington Post's Bezos defends decision to end presidential endorsementsOctober 30 at 4:21 AM | reuters.comOrano Announces Leadership Transition in Orano MedOctober 25, 2024 | finance.yahoo.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2024October 21, 2024 | businesswire.comMedifast (NYSE:MED) Stock Quotes, Forecast and News SummaryOctober 16, 2024 | benzinga.comMEDICLIN (ETR:MED) shareholders have endured a 56% loss from investing in the stock five years agoOctober 11, 2024 | finance.yahoo.comMedifast Inc (MED) Q2 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...October 10, 2024 | finance.yahoo.comShareholders in Medifast (NYSE:MED) are in the red if they invested three years agoSeptember 29, 2024 | finance.yahoo.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $67.22 at the start of the year. Since then, MED shares have decreased by 72.7% and is now trading at $18.38. View the best growth stocks for 2024 here. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) released its quarterly earnings results on Monday, August, 5th. The specialty retailer reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.36 by $0.56. The specialty retailer had revenue of $168.56 million for the quarter, compared to analyst estimates of $160.44 million. Medifast had a net margin of 3.81% and a trailing twelve-month return on equity of 25.77%. Who are Medifast's major shareholders? Top institutional shareholders of Medifast include Values First Advisors Inc. (0.59%), Inspire Investing LLC (0.45%), Robeco Institutional Asset Management B.V. (0.19%) and SG Americas Securities LLC (0.10%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY). Company Calendar Last Earnings8/05/2024Today10/31/2024Next Earnings (Confirmed)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$17.50 Low Stock Price Target$17.50 Potential Upside/Downside-5.4%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.68 Trailing P/E Ratio6.90 Forward P/E Ratio16.51 P/E GrowthN/ANet Income$99.42 million Net Margins3.81% Pretax Margin4.84% Return on Equity25.77% Return on Assets17.04% Debt Debt-to-Equity RatioN/A Current Ratio2.98 Quick Ratio2.46 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.19 Cash Flow$11.48 per share Price / Cash Flow1.61 Book Value$18.50 per share Price / Book1.00Miscellaneous Outstanding Shares10,940,000Free Float10,664,000Market Cap$202.28 million OptionableOptionable Beta1.13 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NYSE:MED) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.